AI assistant
Oric Pharmaceuticals, Inc. — Director's Dealing 2021
Sep 17, 2021
32131_dirs_2021-09-16_44a13bad-20e0-4316-9760-6a97f3252d7c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Oric Pharmaceuticals, Inc. (ORIC)
CIK: 0001796280
Period of Report: 2021-09-14
Reporting Person: Chacko Jacob (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-09-14 | Common Stock | S | 4420 | $25.0467 | Disposed | 6388 | Direct |
| 2021-09-15 | Common Stock | S | 3736 | $25.0612 | Disposed | 2652 | Direct |
Footnotes
F1: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2: Represents the weighted average share price of an aggregate total of 4,420 shares sold in the price range of $25.00 to $25.22 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3: Represents the weighted average share price of an aggregate total of 3,736 shares sold in the price range of $25.00 to $25.25 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.